Terms: = Prostate cancer AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
3 results:
1. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (syk) inhibitor C61.
Sahin TK; Aktepe OH; Uckun FM; Yalcin S
Anticancer Drugs; 2020 Jul; 31(6):609-616. PubMed ID: 32044796
[TBL] [Abstract] [Full Text] [Related]
2. syk is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract] [Full Text] [Related]
3. The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G; Anderson LM
Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164
[TBL] [Abstract] [Full Text] [Related]
